PRO-LAD
N,N-diethyl-6-propyl-9,10-didehydroergoline-8β-carboxamide
Viewing r1 — Apr 27, 2026 — CURRENT
Back to HistoryInteractions, related substances, and reports reflect the current entry and are not shown for historical revisions.
PRO-LAD (6-propyl-6-nor-lysergic acid diethylamide) is a synthetic psychedelic of the lysergamide class. It differs from LSD only by an n-propyl chain at the N⁶ nitrogen, producing a shorter and qualitatively distinct experience. PRO-LAD is a presumed 5-HT₂A receptor agonist, producing its effects by disrupting serotonin-mediated sensory and cognitive filtering.[1]
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
LSD, psilocybin, mescaline +5 moreLSD, psilocybin, mescaline, AL-LAD, ETH-LAD, 1P-LSD, DMT, 2C-B show less
Synthesized and characterized by Hoffman and Nichols at Purdue University in 1985 as part of a systematic study of LSD's nitrogen substituents,[2] PRO-LAD's human effects were first documented by Shulgin in TiHKAL (1997).[3] The compound briefly appeared on the research chemical market circa 2013–2015 before the United Kingdom and several European jurisdictions explicitly scheduled it.[4] It remains unscheduled by name in the United States.
Subjective effects include intellectual clarity, humor enhancement, moderate geometric visual patterns, and pronounced body sensations. The experience is defined by a lucid, grounded headspace with a prominent somatic dimension — tingling, lightness, and numbness throughout the body — that distinguishes it from LSD's more cerebral and visually saturated character.[5] Thought loops, physical tension, and anxious fixation in unsupportive settings are characteristic unsought effects.
PRO-LAD produces no physical dependence, and rapid tolerance after a single dose makes compulsive redosing self-limiting.[1] The primary risk is psychological — acute anxiety, panic, and potential psychotic destabilization in predisposed individuals — scaling with dose and setting rather than cumulative exposure. No clinical studies, receptor binding data, or human pharmacokinetic investigations have been published; the current understanding rests on a single animal study, a handful of first-person accounts, and structural analogy to LSD.
History[edit]
Discovery
PRO-LAD arose from a systematic effort to map the structure-activity relationship of LSD's N⁶ nitrogen. In 1985, Andrew J. Hoffman and David E. Nichols at Purdue University synthesized a series of N⁶-alkyl norlysergic acid diethylamide derivatives, including the propyl variant.[2] Their drug discrimination assays in rats showed PRO-LAD to be equipotent with LSD, placing the three-carbon propyl chain at the boundary of optimal substituent size.[2]
Human documentation
The first published human accounts appeared in Alexander Shulgin's 1997 compendium TiHKAL, entry #51, which relayed personal communications describing effects at oral doses of 80–175 µg.[3] These reports — noting intellectual clarity, humor enhancement, and a 6–8 hour duration — remain the only detailed first-person descriptions in the published record.
Scheduling
PRO-LAD appeared on the research chemical market around 2013–2015, alongside related lysergamides AL-LAD, ETH-LAD, and LSZ.[4] The UK Advisory Council on the Misuse of Drugs recommended Class A scheduling in June 2014 — notably while acknowledging the compound had never been identified as sold or causing documented harm.[6] The Home Office enacted the recommendation on January 7, 2015, and several European jurisdictions followed between 2015 and 2019.[4]
The name PRO-LAD follows the standard lysergamide abbreviation convention: the prefix indicates the N⁶ substituent (propyl), while LAD denotes lysergic acid diethylamide. This parallels ETH-LAD (ethyl) and AL-LAD (allyl).
Chemistry[edit]
Structural class
PRO-LAD belongs to the lysergamide family — ergoline alkaloid derivatives built on a tetracyclic ring system shared with LSD. The molecule consists of an indole nucleus fused to a partially saturated quinoline ring, with a diethylamide group at the C-8β position essential for psychedelic activity. PRO-LAD differs from LSD at a single point: the N⁶ nitrogen carries an n-propyl chain (three carbons, linear) instead of LSD's methyl group.
This substitution is part of a well-characterized structure-activity series — from unsubstituted (nor-LSD) through methyl (LSD), ethyl (ETH-LAD), allyl (AL-LAD), and propyl (PRO-LAD).[2] The propyl chain sits at the boundary of optimal size: longer alkyl groups progressively reduce potency in drug discrimination assays.[2]
| Molecular formula | C₂₂H₂₉N₃O |
| Molecular weight | 351.5 g/mol |
Physical properties and stereochemistry
PRO-LAD retains the (6aR,9R) absolute configuration of d-LSD — only this stereoisomer is pharmacologically active.[9][1] The crystalline free base melts at 87–88°C.[3] The propyl chain modestly increases lipophilicity relative to LSD (XLogP 3.8 versus ~2.9), which may alter how the compound distributes in the body.
Like other lysergamides, PRO-LAD is expected to degrade when exposed to light, oxygen, and chlorinated water — standard storage precautions (light protection, cool and dry conditions) apply by class analogy. No validated analytical detection methods for biological samples have been published.
Pharmacology[edit]
Mechanism of action
PRO-LAD is presumed to act primarily through partial agonism at the serotonin 5-HT₂A receptor, the molecular target responsible for classical psychedelic effects.[1][10] No receptor binding studies specific to PRO-LAD have been published. This assignment rests on three converging lines of evidence: the compound preserves LSD's pharmacophore (ergoline scaffold and diethylamide group); it fully substitutes for LSD in rat drug discrimination, demonstrating equivalent receptor engagement;[2] and all psychoactively potent members of the N⁶-alkyl norlysergamide series share this mechanism.
Beyond 5-HT₂A, lysergamides engage a broad set of targets. LSD acts on 5-HT₁A and 5-HT₂C serotonin receptors, dopamine D₁ and D₂ receptors, and α₁/α₂ adrenergic receptors — a polypharmacological breadth that distinguishes lysergamides from tryptamine psychedelics.[1][11] A 2025 study profiling 41 psychedelics against 318 human receptors confirmed this broad activity pattern for the lysergamide class.[9] PRO-LAD is expected to share this multi-target profile, though direct confirmation is lacking.
A crystal structure of LSD bound to the 5-HT₂B receptor revealed that an extracellular loop acts as a "lid," clamping over the molecule and prolonging its time at the receptor well beyond plasma drug levels.[10] PRO-LAD's bulkier propyl group could plausibly alter this lid-trapping mechanism — a hypothesis consistent with the compound's shorter reported duration — but this has not been experimentally tested.
Pharmacokinetics
No human pharmacokinetic data exist for PRO-LAD. For reference, oral LSD at 100–200 µg reaches peak plasma levels in approximately 1.5 hours, with an initial half-life of ~3.6 hours and a terminal half-life of ~8.9 hours.[12]
PRO-LAD's total duration of 6–8 hours[3] is notably shorter than LSD's 8–12 hours. This difference could reflect faster metabolic clearance, reduced receptor residence time, or both. The propyl chain's increased lipophilicity may alter distribution, but no published data address this directly. No metabolites of PRO-LAD have been identified.
Neuroscience[edit]
Where it acts
Serotonergic psychedelics acting through 5-HT₂A receptors on deep-layer cortical neurons produce a recognizable constellation of brain changes: disruption of the default mode network, reduced thalamic filtering of sensory information, increased connectivity between normally isolated brain networks, and elevated neural entropy.[1] LSD additionally engages dopamine and adrenergic signaling, contributing to reward-circuit activation and sympathetic arousal.[11]
No neuroimaging or electrophysiology studies have been conducted with PRO-LAD, but its structural identity and pharmacological equipotency with LSD predict a broadly similar neural pattern — potentially modulated by the compound's distinct receptor kinetics.
Why it matters
The most explanatory framework for psychedelic neural effects is REBUS (Relaxed Beliefs Under Psychedelics), which proposes that these compounds loosen the brain's high-level predictions, allowing raw sensory input greater influence on conscious experience. PRO-LAD's reported intellectual clarity with reduced cosmic ideation may reflect partial relaxation of perceptual priors without full dissolution of abstract belief structures.
Whether PRO-LAD promotes structural neuroplasticity — dendritic growth and new synaptic connections, as demonstrated for LSD via 5-HT₂A-mediated signaling cascades — has not been investigated.
Does the propyl group alter biased agonism at 5-HT₂A in ways that explain qualitative differences from LSD? Does the shorter duration reflect altered receptor residence time, faster metabolism, or both? Would PRO-LAD produce the same default mode network disruption seen with LSD at equivalent doses, or does its distinct experiential profile predict a different neural signature?
Subjective Effects[edit]
PRO-LAD delivers a psychedelic experience defined by intellectual transparency and somatic presence. The headspace is lucid and analytically clear, with humor enhancement and easy fantasy states — particularly responsive to music.[3] A prominent body component — tingling, numbness, and feelings of lightness — persists across the dose range, giving the experience a distinctly physical character. Set and setting remain primary determinants of outcome.
Compared to LSD, PRO-LAD trades visual intensity and cosmic ideation for greater cognitive clarity and a more pronounced somatic dimension.[5] Its shorter arc positions it between the brief tryptamine experience and LSD's extended commitment, appealing to those seeking a full lysergamide session in a more contained timeframe.
Effect Grid
At common doses (100–150 µg oral), the full PRO-LAD experience develops: visual drifting and pattern recognition emerge, with surfaces showing gentle morphing and color shifting. Closed-eye visuals include geometric patterning, though visual intensity is milder than LSD at comparable doses. Auditory enhancement makes music deeply engaging. Thought connectivity increases substantially, producing novel associations and humor enhancement described as "excellent."
The body component is prominent — numbness, tingling, and a pervasive sense of bodily lightness characterize this range. Mild jaw tension and temperature dysregulation may occur. Nausea is uncommon.
Total duration is 6–8 hours. Sleep becomes possible at the 8th or 9th hour. Appetite returns during the latter portion of the experience.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Visual breathing · Music enhancement · Perspective distortion · Tracers · Auditory enhancement · Brightness alteration · Light sensitivity · Visual morphing · Holotropic state · Symmetrical texture repetition · Depth perception distortion · Environmental patterning · Sound sensitivity · Visual melting · After-images · Auditory distortion · Visual diffraction · Auditory misinterpretation · Peripheral vision distortion · Spatial disorientation · Touch enhancement · Vestibular distortion · Visual haze / noise · Visual acuity enhancement · Visual processing acceleration · Synesthesia · Peripheral misidentification · Proprioceptive distortion · Visual magnification · Tinnitus · Olfactory enhancement · Touch suppression · Flashbacks · Object transformations · External hallucinations · Environmental orbism / cubism · Object activation · Visual recursion · Internal hallucinations · Auditory hallucinations · Perspective hallucinations · Visual flipping · Olfactory hallucination · Persisting hallucinations
Auditory enhancement · Brightness alteration · Light sensitivity · Visual morphing · Holotropic state · Symmetrical texture repetition · Depth perception distortion · Environmental patterning · Sound sensitivity · Visual melting · After-images · Auditory distortion · Visual diffraction · Auditory misinterpretation · Peripheral vision distortion · Spatial disorientation · Touch enhancement · Vestibular distortion · Visual haze / noise · Visual acuity enhancement · Visual processing acceleration · Synesthesia · Peripheral misidentification · Proprioceptive distortion · Visual magnification · Tinnitus · Olfactory enhancement · Touch suppression · Flashbacks · Object transformations · External hallucinations · Environmental orbism / cubism · Object activation · Visual recursion · Internal hallucinations · Auditory hallucinations · Perspective hallucinations · Visual flipping · Olfactory hallucination · Persisting hallucinations
Wakefulness · Spontaneous body sensations · Stimulation · Body high · Insomnia · Laughter fits · Restlessness · Tingling / electric sensations · Muscle tension · Bodily lightness · Nausea · Vibrations / buzzing · Dizziness · Dry mouth · Heart rate perception changes · Motor control impairment · Physical fatigue · Tactile euphoria · Dehydration sensation · Abnormal heartbeat · Excessive sweating · Headache · Bodily pressures · Body schema distortion · Breathing alteration · Trembling · Watery eyes · Bruxism · Involuntary body movements · Nystagmus (eye wobbles) · Sexual arousal enhancement · Yawning · Increased urination · Vomiting · Motor control enhancement · Seizure threshold reduction · Bodily dissociation · Tactile hallucination
Body high · Insomnia · Laughter fits · Restlessness · Tingling / electric sensations · Muscle tension · Bodily lightness · Nausea · Vibrations / buzzing · Dizziness · Dry mouth · Heart rate perception changes · Physical fatigue · Tactile euphoria · Dehydration sensation · Abnormal heartbeat · Excessive sweating · Headache · Bodily pressures · Body schema distortion · Breathing alteration · Trembling · Watery eyes · Bruxism · Involuntary body movements · Nystagmus (eye wobbles) · Sexual arousal enhancement · Yawning · Increased urination · Vomiting · Motor control enhancement · Seizure threshold reduction · Bodily dissociation · Tactile hallucination
Conceptual thinking · Thought connectivity · Pattern recognition enhancement · Immersion enhancement · Cognitive euphoria · Cognitive flexibility · Openness enhancement · Thought acceleration · Increased nature relatedness · Multiple thought streams · Creativity enhancement · Humor enhancement · Thought loops · Memory suppression · Confusion · Analysis enhancement · Cognitive fatigue · Cognitive impairment · Focus suppression · Information processing enhancement · Language suppression · Analysis suppression · Information processing suppression · Memory fragmentation · Synchronicity · Thought disorganization · Focus enhancement · Language enhancement · Cognitive dysphoria · Memory replays · Delusions · Amnesia
Immersion enhancement · Cognitive euphoria · Cognitive flexibility · Openness enhancement · Thought acceleration · Increased nature relatedness · Multiple thought streams · Creativity enhancement · Humor enhancement · Thought loops · Memory suppression · Confusion · Analysis enhancement · Cognitive fatigue · Cognitive impairment · Focus suppression · Information processing enhancement · Language suppression · Analysis suppression · Information processing suppression · Memory fragmentation · Synchronicity · Thought disorganization · Focus enhancement · Language enhancement · Cognitive dysphoria · Memory replays · Amnesia
Empathy enhancement · Simultaneous emotions · Anxiety · Catharsis · Dysphoria
Dysphoria
Sociability enhancement · Trust enhancement · Communication enhancement · Flow state · Communication suppression · Depersonalization · Boundary dissolution · Identity alteration · Ego dissolution · Cognitive disconnection
Communication suppression · Depersonalization · Boundary dissolution · Identity alteration · Ego dissolution · Cognitive disconnection
Time cessation
Transpersonal visions · Death-rebirth sequence · Entity contact · Transpersonal memory access
Recursive awareness
Timeline
First alerts appear as subtle shifts in mood and somatic awareness — mild tingling, slight brightening of visual field. Effects are easily overlooked at threshold doses.
Effects build steadily: color enhancement intensifies, body component emerges (numbness, lightness), and cognitive shifts become unmistakable. Mild anxiety or restlessness may accompany the transition.
Maximum intensity of visual, cognitive, and emotional effects. Visual drifting, pattern recognition, and auditory enhancement are strongest. Intellectual clarity and humor enhancement are most prominent.
Effects maintain a sustained but gradually diminishing intensity. Visuals soften, cognitive flexibility persists, emotional warmth remains. Appetite may begin to return.
Gradual return toward baseline. Residual visual enhancement and mild thought connectivity linger. Physical tension dissipates.
Subtle mood elevation, reflective thinking, and mild perceptual brightness may persist for several hours after primary effects resolve. Sleep is reported as achievable by the 8th or 9th hour.
⚠ Do not drive or operate heavy machinery until after a full night of sleep following PRO-LAD use.
Safety[edit]
- Acute toxicity
- Negligible
- Chronic toxicity
- Negligible
- Withdrawal
- None
- Tolerance buildup
- rapid
- Tolerance reset
- 14 days
- Physical
- None
- Psychological
- Negligible
- Compulsive redosing
- Negligible
- Dose escalation
- Negligible
- Cross-tol.
- LSD · psilo · mesc
Toxicity
No lethal dose, therapeutic index, or controlled toxicity data exist for PRO-LAD in any species. No overdose cases or deaths attributed to the compound have been documented.[5]
By structural analogy with LSD — which is physiologically well tolerated at typical doses with no established lethal dose in humans[1] — acute physical toxicity is expected to be low. The main physical effects are mild sympathetic activation: pupil dilation, slight heart rate increase, and minor blood pressure elevation, all generally benign at psychoactive doses.
Heart and circulation
Ergoline compounds carry a theoretical risk of vasoconstriction, but LSD-type doses fall far below the threshold for clinically significant problems. No cardiovascular events specific to PRO-LAD have been reported.safety citation needed
Adulteration risk
NBOMe compounds (e.g., 25I-NBOMe) are sometimes sold on blotter as lysergamides. These substances are potentially fatal at sub-milligram doses and cannot be identified by appearance or taste.[5] Ehrlich reagent testing (positive indole reaction: purple color) distinguishes ergoline compounds from NBOMe adulterants.[5]
Psychological risks
The principal risks of PRO-LAD, as with all serotonergic psychedelics, are psychological:
- Acute distress: anxiety, panic, and dysphoria can occur at any dose, particularly in unsupportive settings or with pre-existing psychological vulnerability[5]
- Psychosis: Individuals with personal or family history of psychotic spectrum disorders are at elevated risk of acute psychotic episodes or prolonged psychiatric destabilization[1]
- HPPD: Hallucinogen persisting perception disorder — ongoing visual disturbances after psychedelic use — is a documented class risk. Prevalence is poorly established (reported range 0.1–4.2% of psychedelic users) and no PRO-LAD-specific data exist[1]
- Surfaced trauma: Psychedelics can bring repressed traumatic material to the surface, producing acute psychological crisis
No controlled data on adverse psychological event rates exist for PRO-LAD. All risk estimates derive from LSD class data.
Tolerance and dependence
PRO-LAD is not habit-forming. By class analogy with LSD, near-complete tolerance develops after 3–4 consecutive daily doses via 5-HT₂A downregulation.[1] Full tolerance reset takes approximately 14 days. Complete cross-tolerance exists with other serotonergic psychedelics (LSD, psilocybin, mescaline).[1]
LSD and related lysergamides produce no physical dependence, no meaningful compulsive use patterns, and no withdrawal.[1] The rapid onset of tolerance itself limits repeated use.
Drug interactions
No PRO-LAD-specific interaction data have been published. The following concerns derive from LSD class pharmacology.
Dangerous combinations
Tramadol presents a dual risk: its metabolite is a potent serotonin reuptake inhibitor,[13] creating serotonin syndrome risk when combined with a direct 5-HT₂A agonist. Tramadol also independently lowers seizure threshold, compounding the danger.safety citation needed
Lithium combined with LSD is associated with seizures in published case reports. This combination should be considered dangerous for PRO-LAD by class analogy.safety citation needed
Moderating combinations
SSRIs and SNRIs present a bidirectional interaction: chronic use dampens psychedelic effects by downregulating 5-HT₂A receptors; acute co-administration at high doses carries theoretical serotonin syndrome risk.
MAOIs potentiate serotonergic activity and present serotonin syndrome risk when combined with direct 5-HT₂A agonists.
Terminating agents
5-HT₂A antagonists (e.g., risperidone, quetiapine) can end a PRO-LAD experience by displacing the drug from its primary receptor target — relevant for clinical management of acute psychedelic distress.
Contraindications
No PRO-LAD-specific contraindication data exist. By class analogy with LSD:
- Psychotic spectrum disorders: Personal or family history of schizophrenia, schizoaffective disorder, or bipolar I with psychotic features — absolute contraindication[1]
- Lithium use: Seizure risk — absolute contraindicationsafety citation needed
- Tramadol use: Serotonin syndrome and seizure risk[13]
- MAOI use: Serotonin syndrome risk (relative contraindication; depends on type and dose)
- Pregnancy and breastfeeding: No reproductive safety data exist for any lysergamide
Harm Reduction[edit]
Forms & Identification
PRO-LAD is vanishingly rare on unregulated markets and has no established commercial supply chain. When encountered, it typically appears on blotter paper, following the distribution convention of other lysergamides. The critical testing concern is distinguishing ergoline compounds from NBOMe adulterants — a distinction that reagent testing can make. Laboratory confirmation via mass spectrometry provides definitive identification but is impractical for most users; Ehrlich reagent remains the minimum viable screening step.
Guidelines
- Test all material with Ehrlich reagent before use — this is the minimum screening step for any substance sold on blotter
- Start with a low dose if using PRO-LAD for the first time; individual sensitivity varies, and the compound's rarity means batch-to-batch consistency cannot be assumed
- Allow at least 14 days between sessions for full tolerance reset
- Choose a calm, familiar environment with a trusted sitter present
- Have water, light food, and comfortable clothing available — the pronounced body component benefits from physical ease
- Clear the schedule for the full duration plus afterglow; avoid driving or operating machinery for at least 12 hours
Set & Setting
As a serotonergic psychedelic, PRO-LAD's experiential outcome is heavily modulated by mental state (set) and the physical and social environment (setting). The compound's pronounced body component means physical comfort matters more than with some psychedelics — a warm, secure space with room to move is ideal.
TiHKAL accounts note strong responsiveness to music, making auditory environment a meaningful variable.[3] A trusted, sober companion familiar with psychedelic states provides a safety net for navigating difficult moments.
Aftercare & integration. The days following a PRO-LAD experience may include heightened emotional sensitivity and reflective openness. Journaling key impressions, emotions, and insights within 24 hours helps preserve material that fades quickly. Gentle physical activity, adequate sleep, and nutritious food support recovery.
If the experience surfaced difficult emotions or memories, speaking with a trusted friend or a therapist experienced with psychedelic integration can help process the material constructively. Persistent distress, intrusive imagery, or unusual perceptual changes lasting more than a week warrant professional consultation.
Recovery & Support
PRO-LAD does not produce physical dependence or withdrawal, and compulsive use is rare due to rapid tolerance. However, any pattern of psychedelic use driven by avoidance, escapism, or compulsive seeking of peak experiences deserves honest self-assessment.
Resources for those concerned about their relationship with psychedelic use include the Fireside Project (62-FIRESIDE / 623-473-7433), MAPS integration therapist directory, and local harm reduction organizations. Peer support communities familiar with psychedelic experiences can provide non-judgmental space for working through difficult patterns.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency: Most difficult psychedelic experiences are distressing but not medically dangerous. Seek immediate help if someone shows signs of self-harm intent, complete disconnection from reality (unable to recognize people or surroundings), seizures, or severe chest pain. Persistent panic that does not respond to reassurance or environment change also warrants professional intervention.
Immediate steps:
- Move the person to a quiet, low-stimulation environment
- Speak in calm, simple sentences — reassure them the experience is temporary and will end
- Do not physically restrain unless there is immediate danger of self-harm
- If symptoms escalate (seizure, loss of consciousness, self-injury), call emergency services
- Place an unconscious person in the recovery position
What to tell the dispatcher: Name the substance (PRO-LAD, a lysergamide psychedelic similar to LSD), estimated dose, time of ingestion, and current symptoms. Good Samaritan laws in many jurisdictions protect people who call for help during drug-related emergencies.
Legal Status[edit]
PRO-LAD occupies a mixed legal landscape. It is specifically named and controlled in the United Kingdom and several European jurisdictions, while remaining unscheduled by name in the United States and Canada. In jurisdictions without explicit scheduling, structural analog or new psychoactive substance legislation may apply. The UK scheduling is notable for having occurred pre-emptively — the Advisory Council on the Misuse of Drugs acknowledged that PRO-LAD had not been identified as ever having been sold or causing documented harm at the time of its recommendation.[6]
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States | Not explicitly scheduled | Federal Analogue Act potentially applicable as LSD analog if marketed for human consumption |
| United Kingdom | Class A (Misuse of Drugs Act 1971, Schedule 1) | Specifically named in Home Office Circular 001/2015, effective January 7, 2015[4] |
| Germany | Controlled (NpSG) | Scheduled under Neue-psychoaktive-Stoffe-Gesetz, effective July 18, 2019[14] |
| Latvia | Illegal | Specifically listed, effective June 1, 2015[14] |
| Switzerland | Controlled | Added to controlled substances list, effective December 1, 2015[14] |
| Canada | Not explicitly scheduled | Not specifically named; status comparable to other lysergamide analogs[5] |
| Australia | Likely controlled | Controlled as LSD derivative under prohibited substance provisions[5] |
Analog law considerations
In the United States, PRO-LAD is not listed in any schedule of the Controlled Substances Act. However, the Federal Analogue Act (21 U.S.C. § 813) treats any substance "substantially similar" to a Schedule I or II substance as equivalent if intended for human consumption. PRO-LAD's structural relationship to LSD (Schedule I) — differing only at the N⁶ position — makes it a strong candidate for prosecution under this provision.
Judicial application of the Analogue Act has been inconsistent, and possession for analytical or research purposes (without intent for human consumption) falls outside its scope.
references
- [1]
- [2]
- [3]
- [4]
- [5]
- [6]